Clinical Trial Update: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for Arlocabtagene autoleucel (BMS-986393), a GPRC5D-directed CAR T cell therapy, evaluating its use in adults with relapsed or r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Arlocabtagene Autoleucel (BMS-986393)

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING